Form 4: Indivior CAO's Stock Vesting & Tax Withholding

Indivior Pharmaceuticals' Chief Accounting Officer, Woodrow D. Anderson, reported the vesting of performance and restricted stock units, alongside associated tax withholding transactions.

Summary

• Woodrow D. Anderson, Chief Accounting Officer of Indivior Pharmaceuticals, Inc. (INDV), reported transactions related to equity awards.
• On March 3, 2026, 18,364 shares of common stock vested from performance stock units (PSUs), representing 76.6% achievement of the target amount of 23,975 PSUs granted on March 3, 2023.
• Concurrently, 8,283 shares were disposed of at $31.98 per share to satisfy tax withholding obligations associated with the PSU vesting.
• Additionally, 5,946 shares of common stock vested from restricted stock units (RSUs) on March 3, 2026.
• An additional 2,682 shares were disposed of at $31.98 per share to cover tax withholding obligations for the RSU vesting.
• Following these transactions, Mr. Anderson's direct beneficial ownership of common stock is 24,638 shares.
• All derivative securities (PSUs and RSUs) related to these awards are now fully vested and beneficially owned at 0.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine insider transaction related to executive compensation, reflecting the vesting of previously granted equity awards and subsequent tax obligations, which is neither inherently positive nor negative for the company's operational performance.

Positives

• The vesting of performance stock units indicates that performance conditions were met at 76.6%, suggesting the company achieved a significant portion of its set targets.
• The vesting of restricted stock units further contributes to executive compensation, aligning management interests with shareholder value.

Negatives

• A significant number of shares (10,965 total) were disposed of to cover tax withholding obligations, which is a common practice but reduces the executive's direct shareholding.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, as it reports past insider transactions.

Industry Context

StockSavvy.ai notes that executive compensation often includes equity awards like Performance Stock Units (PSUs) and Restricted Stock Units (RSUs), which are designed to align management incentives with long-term shareholder value. The vesting of these units and subsequent disposal of shares for tax withholding are standard and routine events in executive compensation across the pharmaceutical industry.

Comparison to Industry Standards

• StockSavvy.ai observes that equity-based compensation, including performance and restricted stock units, is a common practice across the pharmaceutical industry to attract and retain executive talent and incentivize long-term performance.
• The 76.6% achievement rate for performance conditions is within a reasonable range for such awards, indicating moderate success against set targets, comparable to similar programs at companies like Pfizer or Johnson & Johnson where performance metrics often dictate payout percentages.

Stakeholder Impact

• Shareholders: The transactions represent a routine part of executive compensation, involving the vesting of equity awards and subsequent tax-related share disposals. This is an expected event and does not indicate a change in company fundamentals or strategy.
• Employees: No direct impact on general employees from this executive compensation event.

Key Dates

Recommendation

This Form 4 filing details a routine vesting of executive equity awards and subsequent tax-related share disposals. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transactions are expected and part of standard executive compensation practices.

Keywords

Indivior, INDV, Form 4, Insider Transaction, Stock Vesting, Restricted Stock Units, Performance Stock Units, Executive Compensation, Chief Accounting Officer